Optimized sequential therapy vs 10- and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial

Table 1 Basic overall population and group characteristics

Characteristic	Overall, n = 317	QT-14, n = 107	QT-10, n = 105	OST-14, n = 105	P value
Age in yr, mean ± SD	44.13 ± 15.30	43.37 ± 14.40	43.36 ± 15.9	45.67 ± 15.53	0.46
Sex ratio as male/female	0.98	1.03	1	0.92	0.91
Smoking habit	49 (14.9)	18 (16.4)	14 (12.7)	17 (15.7)	0.62
Gastroduodenal ulcer	47 (14.3)	22 (20)	13 (11.8)	12 (11.1)	0.16
Gastric atrophy	51 (15.5)	14 (12.7)	18 (16.4)	19 (17.6)	0.58
Gastric metaplasia	18 (5.5)	7 (6.4)	8 (7.3)	3 (2.8)	0.26
HP antral density					0.30
+	114 (34.9)	37 (33.9)	37 (33.6)	40 (37)
++	170 (52)	58 (53.2)	56 (50.9)	56 (51.9)
+++	35 (10.7)	11 (10.1)	12 (10.9)	12 (11.1)
HP fundic density					0.74
+	147 (44.8)	54 (49.1)	46 (41.8)	47 (43.5)
++	62 (18.9)	20 (18.2)	22 (20)	20 (18.5)
+++	7 (2.1)	1 (0.9)	2 (1.8)	4 (3.7)

All values are expressed as n (%) unless otherwise stated. +: Sparse; ++: Moderate; +++: Marked. HP: Helicobacter pylori; SD: Standard deviation.

Table 2 Incidence of adverse effects among the study groups

Analysis	QT-10	QT-14	OST-14	P value1
ITT	39%	42.7%	24.7%	0.03
PP	45.1%	49.5%	31.3%	0.01

¹P value of χ² test.

ITT: Intention to treat; PP: Per-protocol.

Table 3 Cost-effectiveness ratio in the three protocols costs, expressed in Moroccan dirhams

Therapeutic protocol	Overall cost of 100 patients	Effectiveness	Cost-effectiveness ratio
QT-10	58710	89.5%	655
QT-14	69190	94.4%	732
OST-14	42710	98.1%	435